About Us

Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has over 20 years of experience working in leadership roles in biotechnology finance, corporate development and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff serves on the board of directors of Sigilon Therapeutics, Inc. Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his MBA with a concentration in finance from the Johnson Graduate School of Management at Cornell University.

Marella Thorell is Executive Vice President and Chief Financial Officer of Seres Therapeutics. She is a seasoned finance and operations expert with over 25 years of experience leading capital strategy, financial planning, accounting operations and building finance organizations at public and private biotechs. She has led several financing transactions, IPO readiness programs, and M&A activities. Most recently Ms. Thorell served as the Chief Financial Officer of Evelo Biosciences. Prior roles include Chief Accounting Officer at Centessa Pharmaceuticals, Chief Financial Officer of Palladio Biosciences, prior to its acquisition by Centessa, and Chief Financial Officer and Chief Operating Officer of Realm Therapeutics. Ms. Thorell began her career at Ernst & Young, LLP, and later worked for Campbell Soup Company in roles of increasing responsibility in finance and human resources. She holds a B.S. in Business from Lehigh University. Ms. Thorell is a Director and Chair of the Audit Committee of ESSA Pharmaceuticals and was previously a director of Vallon Pharmaceuticals prior to its merger in 2023.

Thomas J. DesRosier is the Executive Vice President, Chief Legal Officer and Secretary of Seres. He brings more than 30 years of experience in the biopharmaceutical industry. Prior to joining Seres, he served as Chief Legal and Administrative Officer at ARIAD Pharmaceuticals, and prior to that held the same position at Cubist Pharmaceuticals, where he led the negotiation of the acquisition of Cubist by Merck. Previous to that, he served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer. Prior to his 12-year tenure at Genzyme, Mr. DesRosier held senior legal positions at Wyeth Pharmaceuticals, predecessor Genetic Institute, and E.I. DuPont de Nemours. Mr. DesRosier serves on the board of directors of Avanir Pharmaceuticals where he is Chairman of both the Audit Committee and Compliance Committee. He received his B.A. in chemistry from the University of Vermont and his J.D. from Wake Forest University School of Law.

David Ege is the Executive Vice President and Chief Technology Officer of Seres. He has more than 15 years of experience in the pharmaceutical industry, with a focus on vaccine and biologics manufacturing, facility development and process optimization. Prior to joining Seres, Dr. Ege had been at Merck since 2003, in a variety of technical and leadership roles in R&D and manufacturing, in the U.S. and Switzerland. His most recent role was global lead for digital strategy in Merck’s Manufacturing Division. From 2015-2019, Dr. Ege served as Executive Director of Vaccines & Biologics Manufacturing at Merck’s plant in Elkton, VA where he led bulk manufacturing operations for the Gardasil® and Gardasil9® cervical cancer vaccines, as well as adjuvants and Cancidas® – a broad-based anti-fungal medicine made by fermentation. He has contributed to the successful first-in-class licensure and launch of cervical cancer vaccines, Gardasil® (2006) and Gardasil9® (2014), and a breakthrough cancer immunotherapy, Keytruda® (2014). He graduated summa cum laude from Princeton with a BSE in chemical engineering and earned his Ph.D. in chemical engineering from the University of Pennsylvania. While at Penn, Dave also worked in the University’s Center for Technology Transfer and served as President of the Penn Biotech Group.

Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres. He has over 20 years of combined research experience in microbial ecology, genomics and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including all of Seres’ product candidates and has authored over 65 peer-reviewed publications. His research has focused on microbial physiology and the functional role of microbes in both environmental and human disease applications, and on the development of genomic and functional tools to study microbial systems. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.  He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for NIH’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of various peer-reviewed journals.  He currently serves on the scientific advisory board of Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his B.S. in ecology and evolutionary sciences from the University of New Hampshire and his Ph.D. from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as an NSF Postdoctoral Fellow at Duke University.

Lisa Von Moltke, M.D., is the Executive Vice President and Chief Medical Officer at Seres. She has extensive experience in directing successful development programs, leading clinical teams and interacting with regulatory agencies across multiple areas of medicine. Prior to joining Seres, Dr. Von Moltke worked for Alkermes, Inc., where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development. Prior to joining Alkermes, Dr. Von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head CEP for Japan and China regions. Earlier in her career, Dr. Von Moltke served as Head, Translational Medicine for the Takeda Oncology Company. She has served as President of the American College of Clinical Pharmacology and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. Von Moltke earned a B.A. at Wellesley College and her M.D. from Michigan State University, College of Human Medicine.

Terri Young is the Executive Vice President, Chief Commercial and Strategy Officer at Seres Therapeutics. Prior to joining Seres, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics, where she led development of Sage’s global commercial capabilities, including global marketing, insights and analytics and new product planning. Previously, she held commercial leadership roles of increasing responsibility at Bristol-Myers Squibb, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS® business to become the company’s largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline, where she catalyzed growth for the company’s Urology, Diabetes and NeuroHealth organizations. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina. Dr. Young is a member of the Women in Bio and Healthcare Businesswomen’s Association, and served on the Advisory Board of the Healthcare Businesswomen’s Association.